EP
MXCT icon

Essential Partners’s MaxCyte MXCT Stock Holding History

Essential Partners’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6K Sell
2,115
-1,212
-36% -$1.21K ﹤0.01% 1865
2026
Q1 		$2.34K Buy
3,327
+1,579
+90% +$1.47K ﹤0.01% 1941
2025
Q4 		$2.71K Sell
1,748
-677
-28% -$1.08K ﹤0.01% 1696
2025
Q3 		$3.83K Buy
2,425
+2,258
+1,352% +$3.92K ﹤0.01% 1530
2025
Q2 		$364 Buy
+167
New +$404 ﹤0.01% 1786

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Essential Partners's MXCT Position: Q2 2026 in Review

Essential Partners reduced its MaxCyte (MXCT) stake by 36% in Q2 2026, selling an estimated $1.21K and leaving 2,115 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

Essential Partners first reported a position in MXCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.83K in Q3 2025. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Essential Partners held 2,115 shares of MaxCyte worth $2.6K as of Q2 2026.
  • Essential Partners sold 1,212 MaxCyte shares in Q2 2026, an estimated $1.21K.
  • MaxCyte made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1865 holding.
  • Essential Partners first reported a position in MaxCyte in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's MaxCyte position peaked at $3.83K in Q3 2025.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.